SMARCA4 and non-small cell lung carcinoma: In particular, SMARCA4-deficient NSCLC has been associated with lower levels of STING pathway activation and diminished recruitment of CD4+ and CD8+ T-cells, resulting in poor response to PD-1/PD-L1 blockade [32].